(Last updated: February 12, 2014; last reviewed: February 12, 2014)
|Adverse Effects||Associated ARVs||Onset/Clinical Manifestations||Estimated Frequencya||Risk Factors||Prevention/ Monitoring||Management|
|ARV Toxic Neuropathyb||d4T, ddI||Onset:
||Limit use of d4T and ddI, if possible.
As part of routine care, monitor for symptoms and signs of peripheral neuropathy.
|Discontinue offending agent.
Persistent pain can be difficult to treat; topical capsaicin 8% may be helpful.
Data are Insufficient to Allow the Panel to Recommend Use of any of the Following Modalities in Children:
|a Peripheral neuropathy may be under-reported in children because symptoms are difficult to evaluate in young children.
b HIV infection itself may cause a distal sensory neuropathy that is phenotypically identical to ARV toxic neuropathy.
Key to Acronyms: ARV = antiretroviral; d4T = stavudine; ddI = didanosine; INH = isoniazid; NRTI = nucleoside reverse transcriptase inhibitor